---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report. Covers Cost-effectiveness evidence. 35 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics/cost-effectiveness"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report

<a id="economic-information-and-modeling-report"></a>

## 4 Economic Information and Modeling Report

<a id="heading-4.1"></a>

### 4.1 Modeling Overview

<a id="topic-4.1-1"></a>

#### Summary

The published economic evaluations of HAE prophylaxis collected for this report date from 2018 to 2026, and none evaluates onvuzosiran.

The 2018 ICER final evidence report compared Cinryze, Haegarda, and lanadelumab with no prophylaxis in a Markov model with one-month cycles over a lifetime horizon, from a US health care system perspective with a 3% discount rate. The modeled population had a mean age of 39.6 years, was 68.4% female, and had a baseline rate of 3.39 attacks per month. Against no prophylaxis, the incremental cost-effectiveness ratios were $5,954,000 for Cinryze, $328,000 for Haegarda, and $1,108,000 for lanadelumab, with 0.75, 1.19, and 1.19 QALYs gained. The report concluded that, at the drug prices of 2018, prophylactic treatment “does not meet traditional cost-effectiveness thresholds” in its base case, and that sensitivity analyses produced widely varying findings. Its budget impact analysis of lanadelumab used an annual WAC of $565,557, covered five years without discounting, and reached 13% of the $991 million threshold at WAC.

ICER's 2021 observational real-world evidence update reported incremental costs per QALY gained of $30,070,000 for Cinryze, $13,430,000 for Haegarda, and $12,370,000 for Takhzyro, and states that incremental ratios “can become extreme with small denominators”.

The 2026 NICE draft guidance for England does not recommend donidalorsen. It rests on a company cost-comparison analysis that assumed equal efficacy across long-term prophylactic treatments, and states that the most likely cost-effectiveness estimates for donidalorsen cannot be determined.

The 2018 ICER analysis evaluated the three drugs then approved for long-term prophylaxis of HAE-1/2 (Cinryze, Haegarda, and lanadelumab), and the 2021 ICER update reports results for the same three drugs. No US cost-effectiveness or budget impact analysis of berotralstat, garadacimab, or donidalorsen was identified.

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf); [ICER (2021)](https://icer.org/wp-content/uploads/2020/10/ICER_Aetion_RWE_HAE_Report_082421.pdf); [NICE (2026)](https://www.nice.org.uk/guidance/GID-TA11576/documents/draft-guidance)

<a id="topic-4.1-2"></a>

#### Comparator economic assessment: reference strategy

> “No prophylaxis”

Source: [ICER (2021)](https://icer.org/wp-content/uploads/2020/10/ICER_Aetion_RWE_HAE_Report_082421.pdf)

<a id="topic-4.1-3"></a>

#### Comparator-treatment economic assessment: observational real-world evidence update

| Treatment | “Observational RWE Update Cost per QALY gained” |
| --- | --- |
| “Cinryze” | “$30,070,000” |
| “Haegarda” | “$13,430,000” |
| “Takhzyro” | “$12,370,000” |

Source: [ICER (2021)](https://icer.org/wp-content/uploads/2020/10/ICER_Aetion_RWE_HAE_Report_082421.pdf)

<a id="topic-4.1-4"></a>

#### Comparator economic assessment: interpretation of incremental ratios

> “Due to ratio properties of incremental cost-effectiveness ratios, results can become extreme with small denominators.”

Source: [ICER (2021)](https://icer.org/wp-content/uploads/2020/10/ICER_Aetion_RWE_HAE_Report_082421.pdf)

<a id="topic-4.1-5"></a>

#### Comparator cost-effectiveness model: structure

> “We conducted a cost effectiveness analysis using a Markov model comparing the three drugs approved for long-term prophylaxis of HAE-1/2 (Cinryze, Haegarda, and lanadelumab) with no prophylaxis.”
> “Our target population reflected the weighted average of the baseline characteristics across the three pivotal clinical trials for the interventions, with a mean age of 39.6 years, 68.4% female, mean weights of 88.8 kg (male) and 76.4 kg (female), and a baseline attack rate of 3.39 attacks per month.”
> “The model used one-month cycles over a lifetime horizon.”

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)

<a id="topic-4.1-6"></a>

#### Comparator cost-effectiveness model: base-case incremental results versus no prophylaxis

| Measure | Cinryze | Haegarda | Lanadelumab |
| --- | --- | --- | --- |
| QALYs gained | “0.75” | “1.19” | “1.19” |
| Attacks avoided | “860” | “1,430” | “1,480” |
| Incremental cost-effectiveness ratio, US health system perspective | “$5,954,000” | “$328,000” | “$1,108,000” |
| Cost per attack avoided, US health system perspective | “$5,168” | “$273” | “$892” |

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)

<a id="topic-4.1-7"></a>

#### Comparator cost-effectiveness model: conclusion

> “In summary, at current drug prices, prophylactic treatment for HAE 1/2 does not meet traditional cost-effectiveness thresholds within the health care system perspective under our base case assumptions.”
> “However, there is significant uncertainty in key model assumptions, demonstrated by widely varying cost-effectiveness findings in univariate and multivariable sensitivity analyses.”

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)

<a id="topic-4.1-8"></a>

#### Comparator budget impact analysis: lanadelumab per-patient results

| Average annual per-patient budget impact | At WAC | At net price |
| --- | --- | --- |
| Lanadelumab | “$620,338” | “$478,464” |
| Haegarda/Cinryze/no long-term prophylaxis (49%/49%/2%) | “$524,192” | “$524,192” |
| Difference | “$96,145” | “-$45,729” |

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)

<a id="topic-4.1-9"></a>

#### Comparator budget impact analysis: population results and threshold

> “The annual potential budgetary impact of treating the entire eligible population with lanadelumab over five years did not exceed the $991 million ICER budget impact threshold at any price level, reaching only 13% of the threshold at current WAC (Table 7.2), largely due to the relatively small number of patients eligible for treatment.”
> “Furthermore, lanadelumab, compared to a 49%/49%/2% mix of Haegarda/Cinryze/no long-term prophylaxis, was cost-saving in all cases except at WAC, mainly due to the higher costs associated with prophylactic treatment with Cinryze in the comparator arm.”

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)

<a id="topic-4.1-10"></a>

#### Comparator budget impact analysis: switch from no prophylaxis scenario

> “Under this scenario, the average potential budgetary impacts when using the WAC and net price of lanadelumab were additional per-patient costs of approximately $192,200 and $50,350, respectively (Table 7.3).”

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)

<a id="topic-4.1-11"></a>

#### Health technology assessment of the same-target antisense comparator: England

> “Donidalorsen should not be used for preventing recurrent attacks of hereditary angioedema (HAE) in people 12 years and over.”
> “The company’s base case was a cost-comparison analysis assuming equal efficacy across long-term prophylactic treatments, so utilities were not included.”
> “Because of the uncertainties in the clinical- and cost-effectiveness evidence, it is not possible to determine the most likely cost-effectiveness estimates for donidalorsen.”

Source: [NICE (2026)](https://www.nice.org.uk/guidance/GID-TA11576/documents/draft-guidance)

<a id="topic-4.1-12"></a>

#### Sponsor statement on hereditary angioedema market size

> “The HAE market, including acute and prophylactic treatments, was approximately $3.12 billion in 2024 and is estimated to reach approximately $6.83 billion in global sales by 2032 according to forecasts from Evaluate Pharma (June 9, 2026), with prophylactic treatment representing a significant majority.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-4.1-13"></a>

#### Budget impact framework for a new long-term prophylactic agent

> “We used results from the same model employed for the cost-effectiveness analyses to estimate total potential budget impact.”
> “Potential budget impact was defined as the total differential cost of using each new therapy rather than relevant existing therapy for the treated population, calculated as differential health care costs (including drug costs) minus any offsets in these costs from averted health care events.”
> “Briefly, we evaluate a new drug that would take market share from one or more drugs and calculate the blended budget impact associated with displacing use of existing therapies with the new intervention.”

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)

<a id="topic-4.1-14"></a>

#### Displaced comparator mix

> “We therefore assumed that 2% of patients initiating treatment with lanadelumab would not be on long-term prophylaxis.”
> “We assumed that the other 98% of patients taking a new prophylactic treatment (i.e., lanadelumab) would consist equally of patients who would otherwise have taken either Haegarda (49%) or Cinryze (49%).”

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)

<a id="topic-4.1-15"></a>

#### Time horizon and discounting of a published budget impact analysis

> “All costs were undiscounted and estimated over a five-year time horizon.”
> “The five-year timeframe was of primary interest, given the potential for cost offsets to accrue over time and to allow a more realistic impact on the number of patients treated with the new therapy.”

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)

<a id="topic-4.1-16"></a>

#### Perspective of the underlying economic model

> “The base-case analysis used a US health care system perspective (i.e., focusing on direct medical care costs only) with a 3% discount rate for both costs and health outcomes.”

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)

<a id="topic-4.1-17"></a>

#### US prevalence and the population eligible for long-term prophylaxis

> “When applied to the US population in the next five years, it would put the US prevalence at 6,690 individuals.”
> “In recognition of the fact that not all patients with HAE 1/2 are considered candidates for long-term prophylactic treatment, we assumed that only one-third of the patients were eligible for prophylaxis based on expert opinion, resulting in approximately 2,230 patients eligible for prophylactic treatment.”
> “We assumed equal uptake over five years, which translated to 446 patients initiating treatment each year.”

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)

<a id="topic-4.1-18"></a>

#### US diagnosed prevalence from claims data

> “For 2018, 2019, and 2020, the claims-based algorithm yielded overall annual unadjusted HAE prevalence estimates per 100,000 and number of people diagnosed with HAE of 2.67, 9559; 2.61, 9341; and 2.43, 8694, respectively.”
> “The corresponding estimates based on expert physician analysis were 2.13, 7602; 2.03, 7275; and 1.84, 6595, respectively.”

Source: [Castaldo et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40414286/)

<a id="topic-4.1-19"></a>

#### US population with C1 inhibitor deficiency and prophylaxis use in a patient survey

> “Hereditary angioedema (HAE) caused by C1 inhibitor (C1-INH) deficiency is a rare, debilitating, and potentially fatal genetic disorder that affects <8000 people in the United States.”
> “Of the 737 patients included in the final analysis, 37.3% (n = 275) were prescribed and using on-demand–only treatment and reported treating 67.2% of their HAE attacks.”
> “Of the 62.7% (n = 462) who received prophylactic treatment in addition to having on-demand treatment available, 32.3% (n = 149) received one of the novel SC prophylactic therapies (C1-INH [SC] or lanadelumab).”

Source: [Castaldo et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8133018/)

<a id="topic-4.1-20"></a>

#### Share of US patients treated with long-term prophylaxis and the agents initiated

> “In the United States, approximately 70% of patients with HAE are treated with LTP, primarily non-androgens.”
> “Among patients on LTP, 42% (138/328) initiated Takhzyro (lanadelumab), 30% (97/328) initiated Haegarda (C1 esterase inhibitor [human]), 17% (54/328) initiated Cinryze (C1 esterase inhibitor [human]), and 12% (39/328) initiated Orladeyo (berotralstat) as the index LTP.”

Source: [Tachdjian et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273463/)

<a id="topic-4.1-21"></a>

#### Sponsor estimate of disease frequency

> “HAE is a rare autosomal dominant genetic disorder that affects approximately 1 in 50,000 people worldwide.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-4.1-22"></a>

#### Onvuzosiran dosing interval in development

> “We are developing onvuzosiran as a Q6M and Q3M SC treatment for the prevention of HAE attacks.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-4.1-23"></a>

#### Wholesale acquisition cost of donidalorsen per pen and per year at every 8 weeks

> “Cost of Dawnzera per pen: $57,462.00”
> “every 8-week regimen: $373,503.00”

Source: [MO HealthNet Dawnzera fact blast (2025)](https://mydss.mo.gov/sites/mydss/files/media/file/2025/12/6b%20-%20Dawnzera%20NDFB.docx)

<a id="topic-4.1-24"></a>

#### Estimated annual wholesale acquisition cost of long-term prophylactic agents

| Product | Estimated annual WAC |
| --- | --- |
| Dawnzera (donidalorsen), every 4 weeks | “$747,006” |
| Andembry (garadacimab) | “$685,200” |
| Orladeyo (berotralstat) | “$579,885” |
| Takhzyro (lanadelumab) | “$685,171” |
| Haegarda (C1 esterase inhibitor, subcutaneous) | “$604,152” |
| Cinryze (C1 esterase inhibitor, intravenous) | “$665,224” |

Source: [MO HealthNet Dawnzera fact blast (2025)](https://mydss.mo.gov/sites/mydss/files/media/file/2025/12/6b%20-%20Dawnzera%20NDFB.docx)

<a id="topic-4.1-25"></a>

#### Wholesale acquisition cost of garadacimab

> “Estimated WAC per unit: $57,100”
> “the Andembry autoinjector is $685,200”
> “WAC for the first year of therapy is $742,300”

Source: [MO HealthNet Andembry fact blast (2025)](https://mydss.mo.gov/sites/mydss/files/media/file/2025/12/6a%20-%20Andembry%20NDFB.docx)

<a id="topic-4.1-26"></a>

#### Wholesale acquisition cost of berotralstat

> “ORLADEYO® (berotralstat) 150 mg capsule”
> “$48,487.92 per carton containing 28 capsules”

Source: [BioCryst Pharmaceuticals Colorado WAC disclosure (2026)](https://www.biocryst.com/wp-content/uploads/Colorado-WAC-Disclosure-Orladeyo.pdf)

<a id="topic-4.1-27"></a>

#### Wholesale acquisition cost of oral on-demand sebetralstat

> “Ekterly® (sebetralstat) 300mg tablet $35,614 per 4 tablets carton”

Source: [KalVista Pharmaceuticals Colorado WAC disclosure (2026)](https://www.kalvista.com/wp-content/uploads/2026/05/Colorado-WAC-Disclosure-Ekterly-updated-20260504.pdf)

<a id="topic-4.1-28"></a>

#### Medicare Part B payment limits for physician-administered agents, fourth quarter of 2026

> “Effective October 1, 2026 through December 31, 2026”
> “Payment allowance limits subject to the ASP methodology are based on 2Q26 ASP data.”

Source: [CMS Medicare Part B payment limit file (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip)

| Product | HCPCS code | Short description | Dosage unit | Payment limit ($) |
| --- | --- | --- | --- | --- |
| Lanadelumab (Takhzyro) | “J0593” | “Inj., lanadelumab-flyo, 1 mg” | “1 mg” | “88.340” |
| C1 esterase inhibitor, intravenous (Cinryze) | “J0598” | “C-1 esterase, cinryze” | “10 UNITS” | “67.065” |
| C1 esterase inhibitor, on-demand (Berinert) | “J0597” | “C-1 esterase, berinert” | “10 UNITS” | “79.329” |
| Recombinant C1 esterase inhibitor, on-demand (Ruconest) | “J0596” | “Injection, ruconest” | “10 UNITS” | “37.810” |
| Ecallantide, on-demand (Kalbitor) | “J1290” | “Ecallantide injection” | “1 MG” | “599.616” |

Source: [CMS Medicare Part B payment limit file (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip)

<a id="topic-4.1-29"></a>

#### Federal Supply Schedule and Big Four prices, November 2026

| Product | Package | NDC | Price type | Price ($) |
| --- | --- | --- | --- | --- |
| Lanadelumab | “TAKHZYRO 150MG/ML INJ,SYRINGE,2ML” | “47783-0646-01” | “Big4” | “19571.48” |
| Lanadelumab | “TAKHZYRO 150MG/ML INJ,SYRINGE,2ML” | “47783-0646-01” | “FSS” | “24975.51” |
| Lanadelumab | “TAKHZYRO 150MG/ML INJ” | “47783-0644-01” | “Big4” | “16482.83” |
| Lanadelumab | “TAKHZYRO 150MG/ML INJ” | “47783-0644-01” | “FSS” | “24973.13” |
| Berotralstat | “ORLADEYO 150MG CAP” | “72769-0101-01” | “FSS” | “30292.93” |
| Garadacimab | “ANDEMBRY 200MG/1.2ML AUTOINJECTOR” | “63833-0925-01” | “Big4” | “42741.79” |
| Garadacimab | “ANDEMBRY 200MG/1.2ML AUTOINJECTOR” | “63833-0925-01” | “FSS” | “56239.20” |
| Donidalorsen | “DAWNZERA 80MG/0.8ML INJ,AUTOINJECTOR” | “71860-0103-01” | “Big4” | “43012.76” |
| Donidalorsen | “DAWNZERA 80MG/0.8ML INJ,AUTOINJECTOR” | “71860-0103-01” | “FSS” | “56595.74” |
| C1 esterase inhibitor, subcutaneous | “HAEGARDA 2000UNITS/VIL INJ,SOLN” | “63833-0828-02” | “Big4” | “1751.37” |
| C1 esterase inhibitor, subcutaneous | “HAEGARDA 2000UNITS/VIL INJ,SOLN” | “63833-0828-02” | “FSS” | “2175.77” |
| C1 esterase inhibitor, subcutaneous | “HAEGARDA 3000UNITS/VIL INJ,SOLN” | “63833-0829-02” | “Big4” | “2627.18” |
| C1 esterase inhibitor, subcutaneous | “HAEGARDA 3000UNITS/VIL INJ,SOLN” | “63833-0829-02” | “FSS” | “3263.65” |
| C1 esterase inhibitor, intravenous | “CINRYZE C-1 INHIBITOR 500IU/VIL” | “42227-0083-01” | “Big4” | “2306.86” |
| C1 esterase inhibitor, intravenous | “CINRYZE C-1 INHIBITOR 500IU/VIL” | “42227-0083-01” | “FSS” | “3122.91” |

Source: [Department of Veterans Affairs Federal Supply Schedule pharmaceutical prices (2026)](https://department.va.gov/procurement-acquisition-and-logistics/wp-content/uploads/sites/56/2026/11/TPharmPrices-11-01-2026.xlsx)

<a id="topic-4.1-30"></a>

#### Medicare Part D spending on long-term prophylactic agents, 2024

| Brand | Total spending, 2024 ($) | Beneficiaries, 2024 | Average spending per dosage unit, 2024 ($) | Average spending per beneficiary, 2024 ($) |
| --- | --- | --- | --- | --- |
| Takhzyro (lanadelumab) | “223004902.8” | “512” | “12775.306747” | “435556.45078” |
| Orladeyo (berotralstat) | “77894702.6” | “221” | “1516.0510432” | “352464.71765” |
| Haegarda (C1 esterase inhibitor) | “82014748.23” | “187” | “2952.876629” | “438581.54134” |
| Cinryze (C1 esterase inhibitor) | “33104776.46” | “46” | “3256.1007633” | “719669.05348” |

Source: [CMS Medicare Part D Spending by Drug (2026)](https://data.cms.gov/sites/default/files/2026-06/98218f98-166c-4723-8438-c344a4ef96a6/DSD_PTD_RY26_P04_V10_DY24_BGM.csv)

<a id="topic-4.1-31"></a>

#### Medicare Part D spending on on-demand agents, 2024

| Brand | Total spending, 2024 ($) | Beneficiaries, 2024 | Average spending per dosage unit, 2024 ($) | Average spending per beneficiary, 2024 ($) |
| --- | --- | --- | --- | --- |
| Firazyr (icatibant) | “43713828.6” | “170” | “3553.9698049” | “257140.16824” |
| Icatibant (generic) | “32477428.42” | “658” | “955.46002803” | “49357.793951” |
| Berinert (C1 esterase inhibitor) | “34597556.94” | “63” | “3904.4754475” | “549167.57048” |
| Ruconest (recombinant C1 esterase inhibitor) | “55710878.24” | “128” | “7557.0914596” | “435241.23625” |
| Kalbitor (ecallantide) | “20871584.35” | “36” | “5624.2480059” | “579766.23194” |

Source: [CMS Medicare Part D Spending by Drug (2026)](https://data.cms.gov/sites/default/files/2026-06/98218f98-166c-4723-8438-c344a4ef96a6/DSD_PTD_RY26_P04_V10_DY24_BGM.csv)

<a id="topic-4.1-32"></a>

#### Annual prices of lanadelumab used in a published budget impact analysis

> “We used the cost-effectiveness model to estimate the potential total budgetary impact of lanadelumab in HAE 1/2 patients in the US, at the annual wholesale acquisition cost (WAC) of $565,557, the net price of $423,344, and the cost-effectiveness threshold prices at $50,000, $100,000, and $150,000 per QALY.”

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)

<a id="topic-4.1-33"></a>

#### Annual healthcare cost components before and after starting long-term prophylaxis: US commercial claims

| Cost component, per patient per year | Pre-index | Post-index |
| --- | --- | --- |
| Medical costs, emergency room and inpatient | “$23,060” | “$14,716” |
| Medical costs, outpatient, home health, and other | “$2255” | “$1668” |
| Pharmacy costs, on-demand | “$217,857” | “$167,462” |
| Pharmacy costs, other | “$14,214” | “$4193” |
| Pharmacy costs, long-term prophylaxis | “$0” | “$395,845” |
| Total healthcare costs | “$165,348” | “$515,333” |

Source: [Tachdjian et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273463/)

> “Among patients with at least 1 claim (ie, utilized healthcare services).”

Source: [Tachdjian et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273463/)

<a id="topic-4.1-34"></a>

#### Outcomes reported by a published economic model of long-term prophylaxis

> “Model outcomes of interest included:”
> “Total health care costs (undiscounted and discounted)”
> “Number of attacks”
> “Incremental cost-effectiveness ratios (cost per attack avoided, cost per life-year gained, and cost per QALY gained) of each prophylactic therapy versus no long-term prophylaxis”

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)

<a id="topic-4.1-35"></a>

#### Budget impact outcome and affordability threshold

> “The intent of our revised approach to budgetary impact is to document the percentage of patients that could be treated at selected prices without crossing a budget impact threshold that is aligned with overall growth in the US economy.”
> “For 2018-19, therefore, the five-year annualized potential budget impact threshold that should trigger policy actions to manage access and affordability is calculated to total approximately $991 million per year for new drugs.”

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)

<a id="heading-4.2"></a>

### 4.2 Budget Impact Model

<a id="heading-4.2.1"></a>

#### 4.2.1 Approach and Framework

No evidence found.

<a id="heading-4.2.2"></a>

#### 4.2.2 Perspective and Time Frame

No evidence found.

<a id="heading-4.2.3"></a>

#### 4.2.3 Epidemiology and Eligible Population Inputs

No evidence found.

<a id="heading-4.2.4"></a>

#### 4.2.4 Cost Assumptions

No evidence found.

<a id="heading-4.2.5"></a>

#### 4.2.5 Model Outcomes

No evidence found.

<a id="heading-4.2.6"></a>

#### 4.2.6 Results

<a id="heading-4.2.6.1"></a>

##### 4.2.6.1 Base Case

No evidence found.

<a id="heading-4.2.6.2"></a>

##### 4.2.6.2 Scenario Analyses

No evidence found.

<a id="heading-4.2.7"></a>

#### 4.2.7 Budget impact model discussion

No evidence found.

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
